Management strategies in pancreatic cancer

American Journal of Health-System Pharmacy

Volumn 68, Issue 7, 2011, Pages 573-584

  Campen, Christopher J ^a   Dragovich, Tomislav ^b   Baker, Amanda F ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Antineoplastic agents; Combined therapy; Dosage; Drug information; Gemcitabine; Pancreatic neoplasms; Pharmaceutical services; Pharmacists; Toxicity

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EXATECAN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IPI 926; IRINOTECAN; MARIMASTAT; NANOPARTICLE FORMULATED ALBUMIN STABILIZED PACLITAXEL; OXALIPLATIN; PACLITAXEL DERIVATIVE; PEMETREXED; RADIOSENSITIZING AGENT; SMALL MOLECULE TRANSPORT AGENT; STEROID; TIPIFARNIB; UNCLASSIFIED DRUG; VISMODEGIB;

ADJUVANT THERAPY; ADVANCED CANCER; ANEMIA; ANOREXIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG FEVER; DRUG INFORMATION; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; HAIR LOSS; HAND FOOT SYNDROME; HUMAN; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; NANOTECHNOLOGY; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATIENT CARE; PATIENT MONITORING; PHARMACIST; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RASH; REVIEW; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES;

EID: 79956008277     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100254     Document Type: Review

References (77)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60:277-300.
2. Cancer facts & figures 2009. Atlanta: American Cancer Society; 2009.
3. Fazal S, Saif MW. Supportive and palliative care of pancreatic cancer. JOP. 2007; 8:240-53. (Pubitemid 46522756)
4. Nieto J, Grossbard ML, Kozuch P. Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist. 2008; 13:562-76.
5. Kuvshinoff B, Bryer M. Treatment of resectable and locally advanced pancreatic cancer. Cancer Control. 2000; 7:428-36.
6. Yeo CJ, Cameron JL, Lillemoe KD et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995; 221:721-31.
7. Sohn TA, Yeo CJ, Cameron JL et al. Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000; 4:567-79.
8. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985; 120:899-903. (Pubitemid 15040883)
9. Klinkenbijl JH, Jeekel J, Sahmoud T et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999; 230:776-82.
10. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350:1200-10. (Pubitemid 38339364)
11. Regine WF, Winter KA, Abrams RA et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracilbased chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008; 299:1019-26. (Pubitemid 351347058)
12. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297:267-77. (Pubitemid 46143304)
13. Neoptolemos J, Buchler M, Stocken DD et al. ESPAC-3(v2): a multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol (Meeting Abstracts). 2009; 27(suppl 18):LBA4505.
14. Lowy AM. Neoadjuvant therapy for pancreatic cancer. J Gastrointest Surg. 2008; 12:1600-8.
15. Evans DB, Varadhachary GR, Crane CH et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26:3496-502.
16. Varadhachary GR, Wolff RA, Crane CH et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26:3487-95.
17. Katz MH, Pisters PW, Evans DB et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008; 206:833-46.
18. Loehrer PJ Sr, Powell ME, Cardenes HR et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol (Meeting Abstracts). 2008; 26(suppl 15):4506.
19. Sultana A, Tudur Smith C, Cunningham D et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer. 2007; 96:1183-90. (Pubitemid 46625082)
20. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15:2403-13. (Pubitemid 27251144)
21. Huguet F, Girard N, Guerche CS et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009; 27:2269-77.
22. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 2007; 25:1960-6. (Pubitemid 46972777)
23. Heinemann V, Boeck S, Hinke A et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008; 8:82.
24. Abbruzzese JL, Grunewald R, Weeks EA et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991; 9:491-8.
25. Ueda S, Ogata S, Tsuda H et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas. 2004; 29:e1-8.
26. Dragovich T, Huberman M, von Hoff DD et al. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase Ib trial. Cancer Chemother Pharmacol. 2007; 60:295-303. (Pubitemid 46742546)
27. Grubbs SS, Grusenmeyer PA, Petrelli NJ et al. Is it cost-effective to add erlotinib to gemcitabine in advanced pancreatic cancer? J Clin Oncol (Meeting Abstracts). 2006; 24(suppl 18):6048.
28. Blank P, Dedes K, Szucs T. Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review. Pharmacoeconomics. 2010; 28:629-47.
29. Grunewald R, Kantarjian H, Du M et al. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol. 1992; 10:406-13.
30. Poplin E, Feng Y, Berlin J et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixeddose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009; 27:3778-85.
31. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005; 23:3509-16.
32. Colucci G, Giuliani F, Gebbia V et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer. 2002; 94:902-10. (Pubitemid 34150843)
33. Heinemann V, Quietzsch D, Gieseler F et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006; 24:3946-52. (Pubitemid 46630743)
34. Colucci G, Labianca R, Di Costanzo F et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010; 28:1645-51.
35. Herrmann R, Bodoky G, Ruhstaller T et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007; 25:2212-7. (Pubitemid 46954645)
36. Cunningham D, Chau I, Stocken DD et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009; 27:5513-8.
37. Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002; 20:3270-5. (Pubitemid 34831525)
38. Bramhall SR, Schulz J, Nemunaitis J et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002; 87:161-7.
39. Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004; 22:3776-83. (Pubitemid 41095218)
40. Van Cutsem E, van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004; 22:1430-8. (Pubitemid 41103625)
41. Oettle H, Richards D, Ramanathan RK et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005; 16:1639-45. (Pubitemid 41510138)
42. Stathopoulos GP, Syrigos K, Aravantinos G et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as firstline treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer. 2006; 95:587-92. (Pubitemid 44325898)
43. Abou-Alfa GK, Letourneau R, Harker G et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol. 2006; 24:4441-7. (Pubitemid 46630982)
44. Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009; 27:2231-7.
45. Philip PA, Benedetti J, Fenoglio-Preiser C et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol (Meeting Abstracts). 2007; 25(suppl 18):LBA4509.
46. Kindler HL, Niedzwiecki D, Hollis D et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of cancer and leukemia group B (CALGB). J Clin Oncol (Meeting Abstracts). 2007; 25(suppl 18):4508.
47. Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. Anticancer Drugs. 2008; 19:447-64. (Pubitemid 351556397)
48. Cunningham D, Chau I, Stocken C et al. Phase III randomized comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer. 2005; 12(suppl 3):PS11. Abstract.
49. Conroy T, Desseigne F, Ychou M et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol (Meeting Abstracts). 2010; 28:4010.
50. Oettle H, Pelzer U, Stieler J et al. Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol (Meeting Abstracts). 2005; 23:4031.
51. Pelzer U, Kubica K, Stieler J et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol (Meeting Abstracts). 2008; 26:4508.
52. Gemzar (gemcitabine HCl for injection) package insert. Indianapolis: Eli Lilly and Company; 2010.
53. Ling J, Fettner S, Lum BL et al. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs. 2008; 19:209-16.
54. Rakhit A, Pantze MP, Fettner S et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol. 2008; 64:31-41.
55. Hamilton M, Wolf JL, Rusk J et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res. 2006; 12(7 pt 1):2166-71.
56. Hughes AN, O'Brien ME, Petty WJ et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol. 2009; 27:1220-6.
57. Lynch TJ Jr, Kim ES, Eaby B et al. Epidermal growth factor receptor inhibitorassociated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007; 12:610-21. (Pubitemid 350012125)
58. Eaby B, Culkin A, Lacouture ME. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clin J Oncol Nurs. 2008; 12:283-90.
59. Wacker B, Nagrani T, Weinberg J et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007; 13:3913-21. (Pubitemid 47037599)
60. National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE). http://ctep.cancer. gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf (accessed 2011 Jan 4).
61. Philip PA, Mooney M, Jaffe D et al. Consensus report of the National Cancer Institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009; 27:5660-9.
62. Mahadevan D, Von Hoff D. Tumorstroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2007; 6:1186-97. (Pubitemid 46711982)
63. Garber K. Stromal depletion goes on trial in pancreatic cancer. J Natl Cancer Inst. 2010; 102:448-50.
64. Theunissen J, de Sauvage F. Paracrine hedgehog signaling in cancer. Cancer Res. 2009; 69:6007-10.
65. Thayer SP, di Magliano MP, Heiser PW et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003; 425:851-6. (Pubitemid 37355945)
66. Walter K, Omura N, Hong SM et al. Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. Clin Cancer Res. 2010; 16:1781-9.
67. Olive KP, Jacobetz MA, Davidson CJ et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324:1457-61.
68. National Cancer Institute. A study evaluating IPI-926 in combination with gemcitabine in patients with metastatic pancreatic cancer. www.clinicaltrials. gov/ct/show/NCT01130142 (accessed 2011 Feb 10).
69. National Cancer Institute. GDC-0449 and erlotinib hydrochloride with or without gemcitabine hydrochloride in treating patients with metastatic pancreatic cancer or solid tumors that cannot be removed by surgery. www.clinicaltrials.gov/ ct2/show/NCT00878163 (accessed 2011 Jan 4).
70. National Cancer Institute. Gemcitabine hydrochloride with or without GDC-0449 in treating patients with recurrent or metastatic pancreatic cancer. www.clinicaltrials.gov/ct2/show/ NCT01064622 (accessed 2011 Jan 4).
71. Von Hoff DD, Ramanathan R, Borad M et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: a phase I/ II study. J Clin Oncol (Meeting Abstracts). 2009; 27(suppl 15):4525.
72. Von Hoff DD. Epithelium and stroma: double trouble. Paper presented at American Association for Cancer Research Annual Meeting. Washington, DC; 2010 Apr.
73. Abraxis BioScience LLC. Trial of patients with metastatic adenocarcinoma of the pancreas. www.clinicaltrials.gov/ct2/ show/NCT00844649 (accessed 2011 Jan 4).
74. Infante JR, Matsubayashi H, Sato N et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007; 25:319-25. (Pubitemid 350003021)
75. Sato N, Fukushima N, Maehara N et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene. 2003; 22:5021-30. (Pubitemid 37026400)
76. Gao J, Song J, Huang H et al. Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer. J Exp Clin Cancer Res. 2010; 29:28.
77. Desai NP, Trieu V, Hwang LY et al. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs. 2008; 19:899-909.